Skip to content
10-Q

Quarterly Report

Corbus Pharmaceuticals Holdings, Inc. CRBP

0001193125-26-219707

← back to feed
Filed
May 12, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 8, 2026 18.53M sh
Shares Diluted Q1 2026 · Mar 31, 2026 18.71M sh
Shares Diluted Q1 2026 · Mar 31, 2025 12.2M sh
Capex Q1 2026 · Mar 31, 2026 $6K
Capex Q1 2026 · Mar 31, 2025 $0
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$25.57M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$16.42M
Short Term Investments Q1 2026 · Mar 31, 2026 $112.56M
Short Term Investments Q1 2026 · Dec 31, 2025 $134.78M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $25.66M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $28.49M
Stockholders Equity Q1 2026 · Mar 31, 2026 $126.34M
Stockholders Equity Q1 2026 · Dec 31, 2025 $147.5M
Stockholders Equity Q1 2026 · Mar 31, 2025 $127.11M
Stockholders Equity Q1 2026 · Dec 31, 2024 $142.43M
Current Liabilities Q1 2026 · Mar 31, 2026 $18.14M
Current Liabilities Q1 2026 · Dec 31, 2025 $20.69M
Total Liabilities Q1 2026 · Mar 31, 2026 $18.14M
Total Liabilities Q1 2026 · Dec 31, 2025 $20.69M
Current Assets Q1 2026 · Mar 31, 2026 $143.57M
Current Assets Q1 2026 · Dec 31, 2025 $166.95M
Total Assets Q1 2026 · Mar 31, 2026 $144.48M
Total Assets Q1 2026 · Dec 31, 2025 $168.2M
Eps Diluted Q1 2026 · Mar 31, 2026 −$1.23
Eps Diluted Q1 2026 · Mar 31, 2025 −$1.39
Eps Basic Q1 2026 · Mar 31, 2026 −$1.23
Eps Basic Q1 2026 · Mar 31, 2025 −$1.39
Sga Expense Q1 2026 · Mar 31, 2026 $4.49M
Sga Expense Q1 2026 · Mar 31, 2025 $4.13M
Rd Expense Q1 2026 · Mar 31, 2026 $19.82M
Rd Expense Q1 2026 · Mar 31, 2025 $15.64M
Net Income Q1 2026 · Mar 31, 2026 −$22.97M
Net Income Q1 2026 · Mar 31, 2025 −$16.98M
Operating Income Q1 2026 · Mar 31, 2026 −$24.3M
Operating Income Q1 2026 · Mar 31, 2025 −$19.78M